ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FR?) positive, platinum-resistant ovarian cancerELAHERE represents the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback